Adenosine and cerebral ischemia: Therapeutic future or death of a brave concept?

European Journal of Pharmacology

Volumn 365, Issue 1, 1999, Pages 9-25

  Von Lubitz, Dag K J E ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Adenosine; Adenosine receptor; Cerebral ischemia; Stroke; Treatment

Indexed keywords

ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A3 RECEPTOR;

BRAIN BLOOD FLOW; BRAIN ISCHEMIA; BRAIN METABOLISM; HEART PROTECTION; HUMAN; HYPOTENSION; HYPOTHERMIA; MORBIDITY; MORTALITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; STROKE;

EID: 0033556425     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00788-2     Document Type: Article

References (290)

1. 3 receptors in rat brain. Mol. Pharmacol. 48:1995;1038-1045.
2. 3 receptor, pathophysiological significance and therapeutic implications for neurodegenerative disorders. Ann. N.Y. Acad. Sci. 825:1997;11-12.
3. 3 receptor mediates cell spreading, reorganization of actin cytoskeleton, and distribution of Bcl-XL: studies in human astroglioma cells. Biochem. Biophys. Res. Commun. 2:1997;297-304.
4. Abramson N.S., Safar P., Detre K.M., Kelsey S.F., Monroe J., Reinmuth O., Snyder J.V. Neurologic recovery after cardiac arrest: effect of duration of ischemia. Brain Resuscitation Clinical Trial I Study Group. Crit. Care Med. 11:1985;930-931.
5. Åden U., Lindström K., Bona E., Hagberg H., Fredholm B.B. Changes in adenosine receptors in the neonatal rat brain following hypoxic ischemia. Mol. Brain Res. 23:1994;354-358.
6. Albers G.W. Management of acute ischemic stroke: an update for primary care physicians. West J. Med. 166:1997;253-262.
7. 2+-ionophore-induced secretion in a rat mast cell line. J. Pharmacol. Exp. Ther. 2:1996;837-845.
8. Altura B.T., Memon Z.I., Zhang A., Cheng T.P., Silverman R., Cracco R.Q., Altura B.M. Low levels of serum ionized magnesium are found in patients early after stroke which result in rapid elevation of free calcium and spasm of vascular muscle cells. Neurosci. Lett. 230:1997;37-40.
9. + conductance. Pflügers Arch. 419:1991;288-295.
10. 1 receptor-mediated inhibitory tonus: pre and postsynaptic components. Neuroscience. 3:1993;555-565.
11. Anderson R., Sheehan M.J., Strong P. Characterization of the adenosine receptors mediating hypothermia in the conscious mouse. Br. J. Pharmacol. 4:1994;1386-1390.
12. Andine P., Rudolphi K.A., Fredholm B.B., Hagberg H. Effect of propentofylline (HWA 285) on extracellular purines and excitatory amino acids in CA1 of rat hippocampus during transient ischemia. Br. J. Pharmacol. 4:1990;814-818.
13. Araki T., Kato H., Kogure K., Kanai Y. Long term changes in gerbil neurotransmitter receptors following transient cerebral ischemia. Br. J. Pharmacol. 107:1992;437-442.
14. + transport in canine brain. Stroke. 6:1981;726-730.
15. 6-(3-iodobenzyl)adenosine-5′-N-methyluronamide protects against myocardial stunning and infarction without hemodynamic changes in conscious rabbits. Circ. Res. 6:1997;800-809.
16. Ballarin M., Fredholm B.B., Ambrosi S., Mahy N. Extracellular levels of adenosine and its metabolites in the striatum of awake rats: inhibition of uptake and metabolism. Acta Physiol. Scand. 142:1991;97-103.
17. Barth A., Newell D.W., Nguyen L.B., Winn H.R., Wender R., Meno J.R., Janigro D. Neurotoxicity in organotypic hippocampal slices mediated by adenosine analogues and nitric oxide. Brain Res. 762:1997;79-88.
18. Becker B.F., Zahler S., Seligmann C., Kupatt C., Habazettl H. Interaktion Von Adenosin mit Leukozyten und Thrombocyten. Z. Kardiol. 85(6):1996;161-170.
19. Bell M.J., Kochanek P.M., Carcillo J.A., Mi Z., Schding J.K., Wisniewski S.R., Clark R.S.B., Dixon C.E., Marion D.W., Jackson E. Interstitial adenosine, inosine, and hypoxanthine are increased after experimental traumatic brain injury in the rat. J. Neurotrauma. 3:1998;163-170.
20. Bhardwaj A., Northington F.J., Koehler R.C., Stiefel T., Hanley D.F., Trystman R.J. Adenosine modulates N-methyl-D-aspartate-stimulated hippocampal nitric oxide production in vivo. Stroke. 26:1995;1627-1633.
21. 1 receptor-mediated activation of phospholipase C in cultured astrocytes depends on the level of receptor expression. J. Neurosci. 13:1997;4956-4964.
22. 1 receptor agonists as clinically viable agents for treatment of ischemic brain damage. Ann. N.Y. Acad. Sci. 825:1997;23-29.
23. Böhm S.K., Grady E.F., Bunnett N.W. Regulatory mechanisms that modulate signaling by G-protein-coupled receptors. Biochem. J. 322:1997;1-18.
24. Bonser R.W., Thompson N.T., Randall R.W., Garland L.G. Phospholipase D activation is functionally linked to superoxide generation in the human neutrophil. Biochem. J. 2:1990;617-620.
25. 3 receptors. J. Immunol. 11:1997;5400-5408.
26. 3 receptor agonists inhibit macrophage necrosis factor-alpha production in vitro and in vivo. Cell. Mol. Biol. 3:1997;345-349.
27. Boyd M., Meshulam Y., Jacobson K.A., Von Lubitz D.K.J.E. Effect of A1 adenosine receptor agonist and antagonist on glutamic acid release from cortical tissue in vitro. FASEB J. 10:1996;A159.
28. 2 receptors. Br. J. Pharmacol. 2:1985;407-415.
29. 2A adenosine receptor inhibits nitric oxide production in glial cells. FEBS Lett. 429:1998;139-142.
30. Broome M.R., Collingridge G.L., Irving A.J. Activation of the NO-cGMP signaling pathway depresses hippocampal synaptic transmission through an adenosine receptor-dependent mechanism. Neuropharmacology. 11:1994;1511-1513.
31. Brown G.C. Nitric oxide inhibition of cytochrome oxidase and mitochondrial respiration: implications for inflammatory, neurodegenerative, and ischemic pathologies. Mol. Cell. Biochem. 1-2:1997;189-192.
32. Brown et al., 1990.
33. Brundege J.M., Dunwiddie T.M. Modulation of excitatory synaptic transmission by adenosine released from single hippocampal pyramidal neurons. J. Neurosci. 18:1996;5603-5612.
34. Bruns R.F. Role of adenosine in energy supply/demand balance. Nucleos. Nuclet. 10:1991;941-943.
35. Bulley S.R., Wittnich C. Adenosine infusion: a rational approach towards induced hypotension. Can. J. Cardiol. 4:1995;327-334.
36. Caplan L.R. New therapies for stroke. Arch. Neurol. 54:1997;1222-1224.
37. Carswell H.V., Graham D.I., Stone T.W. Kainate-evoked release of adenosine from hippocampus of the anaesthetized rat: possible involvement of free radicals. J. Neurochem. 68:1997;240-247.
38. 1 receptor activation inhibits basal accumulation of inositol phosphates in rat hippocampus. Pharmacol. Toxicol. 4:1998;189-192.
39. Cass, C., 1995. Nucleoside transport. In: Georgopapakou, H. (Ed.), Drug Transport in Antimicrobial and Anticancer Chemotherapy. Marcel Dekker, New York, pp. 403-451.
40. Cavannagh S.P., Gough M.J., Homer-Vanniasinkam S. The role of neutrophil in ischemia-reperfusion injury: potential therapeutic interventions. Cardiovasc. Surg. 2:1998;112-118.
41. Clark R.K., Lee E.V., White R.F., Jonak Z.L., Feuerstein G.Z., Barone C. Reperfusion following stroke hastens inflammation and resolution of ischemic injured tissue. Brain Res. Bull. 4:1994;387-392.
42. Clifton G.L. Hypothermia and hyperbaric oxygen as treatment modalities for severe brain injury. New Horiz. 3:1995;474-478.
43. Colbourne F., Sutherland G., Corbett D. Postischemic hypothermia: a critical appraisal with implications for clinical treatment. Mol. Neurobiol. 3:1997;171-201.
44. Coney A.M., Marshall J.M. Role of adenosine and its receptors in the vasodilation induced in the cerebral cortex of the rat by systemic hypoxia. J. Physiol. (London). 2:1998;507-518.
45. Cook M.A., Karmazyn M. Cardioprotective actions of adenosine and adenosine analogs. EXS. 76:1996;325-344.
46. Cronstein, B., 1997. Adenosine regulation of neutrophil function and inhibition of inflammation via adenosine receptors. In: Jacobson, K.A., Jarvis, M.J. (Eds.), Purinergic Approaches in Experimental Therapeutics. Wiley-Liss, New York, pp. 285-299.
47. Cronstein B.N., Levin R.I., Belanoff J., Weissman G., Hirschhorn R. Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells. J. Clin. Invest. 78:1986;760-770.
48. Cunietti E., Gandini R., Mascaro G., Ferrari M., Pappalepore V., Scapellato L. Defective platelet aggregation and increased platelet turnover in patients with myelofibrosis and other myeloproliferative diseases. Scand. J. Hematol. 4:1981;339-344.
49. 1 receptor ligands on energy metabolism and macromolecular biosynthesis in cultured central neurons. Biochem. Pharmacol. 55:1998;141-149.
50. 1 receptors, guanine nucleotide and forskollin binding sites following transient brain ischemia: a quantitative autoradiographic study. Brain Res. 491:1989;212-226.
51. 2 receptors? Pharmacol. Ther. 3:1996;325-335.
52. 1 receptors in the CA1 region of rat hippocampus: a quantitative autoradiographic study. Brain Res. 446:1988;161-164.
53. Delaney S.M., Geiger J.D. Levels of endogenous adenosine in rat striatum II: regulation of basal and N-methyl-D-aspartate-induced levels by inhibitors of adenosine transport and metabolism. J. Exp. Pharmacol. Ther. 285:1998;568-572.
54. Delaney S.M., Shepel P.N., Geiger J.D. Levels of endogenous adenosine in rat striatum I: regulation by inotropic glutamate receptors, nitric oxide and free radicals. J. Exp. Pharmacol. Ther. 285:1998;561-567.
55. DeLeo J., Toth L., Schubert P., Rudolphi K.A., Kreutzberg G.W. Ischemia-induced neuronal cell death, calcium accumulation, and glial response in the hippocampus of the Mongolian gerbil and protection by propentofylline (HWA 285). J. Cereb. Blood Flow Metab. 7:1987;745-752.
56. Del Zoppo G.J. Why all drugs work in animals but none in stroke patients? Drugs promoting blood flow. J. Intern. Med. 1:1995;79-88.
57. Del Zoppo G.J. Microvascular responses to cerebral ischemia/inflammation. Ann. N.Y. Acad. Sci. 823:1997;132-147.
58. Del Zoppo G.J., Von Kummer R., Hamann G.F. Ischemic damage of brain microvessels: inherent risks for thrombolytic treatment of stroke. J. Neurol. Neurosurg. Psych. 65:1998;1-10.
59. 1 receptor activation. Neuroreport. 6:1995;1097-1100.
60. De Mendonça A., Ribeiro J.A. Adenosine inhibits the NMDA receptor-mediated excitatory postsynaptic potential in the hippocampus. Brain Res. 606:1993;351-356.
61. Diener H.C., Cunha L., Forbes C., Sivenius J., Smets P., Lowenthal A. European Stroke prevention Study. 2. Dipyridamole and salicylic acid in the secondary prevention of stroke. J. Neurol. Sci. 143:1996;1-13.
62. Dimitriadou V., Rouleau A., Trung Tuong M.D., Newklands G.J., Milller H.R., Luffau G., Schwartz J.C., Garbarg M. Functional relationships between sensory nerve fibers and mast cells of dura mater in normal and inflammatory conditions. Neuroscience. 3:1997;829-839.
63. Dirnagl U., Niwa K., Sixt G., Villinger A. Cortical hypoperfusion after global forebrain ischemia in rats is not cause by microvascular leukocyte plugging. Stroke. 5:1994;1028-1038.
64. Domanska-Janik K. Protein serine/threonine kinases (PKA, PKC, and CaMKII) involved in ischemic brain pathology. Acta Neurobiol. Exp. 2:1996;579-585.
65. Domanska-Janik K., Pylowa S., Zalewska T. Coupling of adenosine receptors to adenylate cyclase in postischemic rat brain. Cell. Signal. 5:1993;337-343.
66. Dresse A., Chevolet C., Delapierre D., Masset H., Weisenberger H., Bozler G., Heinzel G. Pharmacokinetrics of oral dipyridamole (Persantine) and its effect on platelet adenosine uptake in man. Eur. J. Clin. Pharmacol. 3:1982;229-243.
67. 1 mediated responses in rat hippocampus. J. Neurosci. 2:1997;607-614.
68. Dux E., Fastbom J., Ungerstedt U., Rudolphi K., Fredhom B.B. Protective effect of adenosine and a novel xanthine derivative propentofylline on the cell damage after bilateral occlusion in the gerbil hippocampus. Brain Res. 2:1990;248-256.
69. During M.J., Spencer D.D. Adenosine: a potential mediator of seizure arrest and postictal refractoriness. Ann. Neurol. 5:1992;618-624.
70. Dyker A.G., Lees K.R. The rationale for new therapies in acute ischaemic stroke. J. Clin. Pharm. Ther. 21:1996;377-391.
71. Farci F.M., Brian J.E. Nitric oxide and the cerebral circulation. Stroke. 3:1994;692-703.
72. Farinelli S.E., Greene L.A., Friedman W.J. Neuroprotective actions of dipyridamole on cultured CNS neurons. J. Neurosci. 14:1998;5112-5123.
73. Fassbender K., Rossol S., Kammer T., Daffertrshofer M., Wirth S., Dollman M., Hennerici M. Proinflammatory cytokines in serum of patients with acute cerebral ischemia: kinetics of secretion and relation to the extent of brain damage and outcome of disease. J. Neurol. Sci. 2:1994;135-139.
74. 2B receptors. Pharmacol. Rev. 4:1997;381-402.
75. 2B receptors: a novel therapeutic target in asthma. Trends Pharmacol. Sci. 4:1998;148-153.
76. Ferré S., Fuxe K., von Euler G., Johansson B., Fredholm B.B. Adenosine-dopamine interactions in the brain. Neuroscience. 3:1992;501-512.
77. Ferré S., Fredholm B.B., Morelli M., Popoli P., Fuxe K. Adenosine-dopamine receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci. 10:1997;482-487.
78. 2 receptors. Glia. 2:1986;152-160.
79. 2B receptors mediate an increase in interleukin (IL)-6-mRNA protein synthesis in human astroglioma. J. Neurochem. 4:1996;1426-1431.
80. Fisher M. Potentially effective therapies for acute ischemic stroke. Eur. Neurol. 1:1995;3-7.
81. Fisher M. Characterizing the target of acute stroke therapy. Stroke. 28:1997;866-872.
82. 3 receptors potentiate hippocampal calcium current by a PKA-dependent/PKC-independent pathway. Neuropharmacology. 3:1997;353-362.
83. Forbes C.D. European stroke prevention study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. Int. J. Clin. Pract. 5:1997;205-208.
84. Fowler J. Purine release and inhibition of synaptic transmission during hypoxia and hypoglycemia in rat hippocampal slices. Neurosci. Lett. 157:1993;83-86.
85. 3 receptor activation in rats. Eur. J. Pharmacol. 3:1996;293-297.
86. Fredholm B.B. Adenosine and neuroprotection. Int. Rev. Neurobiol. 40:1997;259-280.
87. Fredholm B.B., Lindström K. The xanthine derivative 1-(5′-oxohexyl)-3-methyl-7-propylxanthine (HWA 285) enhances actions of adenosine. Acta Pharmacol. Toxicol. 58:1986;187-192.
88. Fredholm B.B., Dunwiddie T.V. How does adenosine inhibit transmitter release? Trends Pharmacol. Sci. 9:1988;130-134.
89. 2A receptors - where are they? What do they do? Trends Pharmacol. Sci. 2:1998;46-48.
90. Fredholm B.B., Abbrachio M.P., Burnstock G., Daly J.W., Harden T.K., Jacobson K.A., Leff P., Williams M. Nomenclature and classification of purinoceptors. Pharmacol. Toxicol. 65:1994;347-351.
91. Fredholm B.B., Lindström K., Wallman-Johansson A. Propentofylline and other adenosine transport inhibitors increase the efflux of adenosine following electrical or metabolic stimulation of rat hippocampal slices. J. Neurochem. 62:1994;563-573.
92. 1 receptors. In: Belardinelli, L., Pelleg, A. (Eds.), Adenosine and Adenine Nucleotides: From Molecular Biology to Integrative Physiology. Kluwer Academic Publishers, Boston, pp. 103-112.
93. 2 receptor antagonist, reduces cerebral ischemic injury in the Mongolian gerbil. Life Sci. 55:1994;61-65.
94. Garcia J.H., Lassen N.A., Weiller C., Sperling B., Nakagawara J. Ischemic stroke and incomplete infarction. Stroke. 27:1996;761-765.
95. 2-receptors are require to stimulate microglial proliferation. Neurochem. Int. 1:1996;37-42.
96. Gerber U., Greene R.W., Haas H.L., Stevens D.R. Characterization of inhibition mediated by adenosine in the hippocampus of the rat in vitro. J. Physiol. (London). 417:1989;567-578.
97. Gidday J.M., Kim Y.B., Shah A.R., Gonzales E.R., Park T.S. Adenosine transport inhibition ameliorates postischemic hypoperfusion in pigs. Brain Res. 1-2:1996;261-268.
98. Ginsberg M.D. The new language of cerebral ischemia. Am. J. Neuroradiol. 18:1997;1435-1445.
99. Ginsberg M., Busto R. Combating hyperthermia in acute stroke: a significant clinical concern. Stroke. 29:1998;529-534.
100. Ginsberg M.D., Sternau L.L., Globus M.Y., Dietrich W.D., Busto R. Therapeutic modulation of brain temperature: relevance to ischemic brain injury. Cerebrovasc. Brain Metab. Rev. 3:1992;189-225.
101. Glowinski J., Marin P., Tence M., Stella N., Giaume C., Premont J. Glial receptors and their intervention in astrocyto-astrocytic and astrocyto-neuronal interactions. Glia. 2:1994;201-208.
102. 3H ] cyclohexyladenosine J. Neurosci. 9:1982;1230-1241.
103. Grace P.A. Ischaemia-reperfusion injury. Br. J. Surg. 5:1994;637-647.
104. 1 adenosine receptor agonist. J. Biol. Chem. 265:1990;5206-5210.
105. Guieu R., Couraud F., Pouget J., Sampieri F., Bechis G., Roachat H. Adenosine and the nervous system: clinical implications. Clin. Neuropharmacol. 6:1996;459-474.
106. Hagberg H., Andersson P., Lacarewicz J., Jacobson I., Butcher S., Sandberg M. Extracellular adenosine, inosine, hypoxanthine, and xanthine in relation to tissue nucleotides and purines in rat striatum during transient ischemia. J. Neurochem. 49:1987;227-231.
107. 1 receptor binding reduces hypoxic-ischemic brain injury in newborn rats. Brain Res. 759:1997;309-312.
108. Hallenbeck J.M. Significance of the inflammatory response in brain ischemia. Acta Neurochir. Suppl. 66:1996;27-31.
109. Hammond C., Crepel V., Gozian H., Ben-Ari Y. Anoxic LTP sheds light on the multiple facets of NMDA receptors. Trends Neurosci. 11:1994;497-503.
110. Hansen, A.J., 1990. Ion homeostasis in cerebral ischemia. In: Shurr, A., Rigor, B.M. (Eds.), Cerebral Ischemia and Resuscitation. CRC Press, Boca Raton, FL, pp. 77-87.
111. Hegedus K., Fekete I., Molnar L. Effects of dipyridamole in spontaneously hypertensive rabbits with diffuse chronic cerebral ischemia. Eur. J. Pharmacol. 2-3:1993;293-298.
112. Hegedus K., Keresztes T., Fekete I., Molnar L. Effect of I.V. dipyridamole on cerebral blood flow, blood pressure, plasma adenosine concentration and cAMP levels in rabbits. J. Neurol. Sci. 2:1997;153-161.
113. 1AR mRNA expression or G protein α-subunit content. J. Neurochem. 71:1998;221-230.
114. Higgins M.J., Hosseinzadeh H., MacGregor D.G., Ogilvy H., Stone T.W. Release and actions of adenosine in the central nervous system. Pharm. World Sci. 2:1994;62-68.
115. 3 receptors mediating physiological or pharmacological protection from ischemic myocardial injury in the rabbit heart. J. Mol. Cell. Cardiol. 3:1998;579-585.
116. Hobson B., Denkamp J. Endothelial proliferation in tumors and normal tissue: continuous labeling studies. Br. J. Cancer. 4:1984;405-413.
117. Hoehn K., White T.D. N-methyl-D-aspartate, kainate, and quisqualate release endogenous adenosine from rat cortical slices. J. Neurochem. 54:1990;256-265.
118. Hoehn K., White T.D. Role of excitatory amino acids receptors in K+ and glutamate-evoked release of endogenous adenosine from rat cortical slices. J. Neurochem. 54:1990;256-265.
119. Horn M., Schlote W. Delayed neuronal death and delayed neuronal recovery in the human brain following global ischemia. Acta Neuropathol. (Berlin). 1:1992;79-87.
120. Hossman K.A. Reperfusion of the brain after global ischemia: hemodynamic disturbances. Shock. 2:1997;95-101.
121. Hunter A.J., Green A.R., Cross A.J. Animal models of acute ischemic stroke: can they predict clinically successful neuroprotective drugs? Trends Pharmacol. Sci. 4:1995;123-128.
122. Hund E., Grau A., Hacke W. Neurocritical care for acute ischemic stroke. Neurol. Crit. Care. 3:1995;511-527.
123. Iadecola C. Bright and dark sides of nitric oxide in ischemic injury. Trends Neurosci. 3:1997;132-139.
124. Iadecola C., Pellegrino D.A., Moskowitz M.A., Lassen N.A. State of the art review: nitric oxide synthase inhibition and cerebrovascular regulation. J. Cereb. Blood Flow Metab. 14:1994;175-192.
125. 3 adenosine receptor: design of selective ligands and therapeutic prospects. Drugs of the Future. 20:1995;689-699.
126. Jacobson K.A., Von Lubitz D.K.J.E., Daly J.W., Fredholm B.B. Adenosine receptor ligands: differences with acute versus chronic treatment. Trends Pharmacol. Sci. 17:1996;108-113.
127. Janigro D., Wender R., Ransom G., Tinklepaugh D.L., Winn H.R. Adenosine-induced release of nitric oxide from cortical astrocytes. Neuroreport. 7:1996;1640-1644.
128. Jarvis, M.F., Williams, M., 1989. Adenosine in central nervous system function. In: Williams, M. (Ed.), Adenosine and Adenosine Receptors. Humana Press, Clifton, pp. 423-474.
129. 3 receptors. Drug Dev. Res. 33:1994;51-59.
130. Jiang N., Kowaluk E.A., Lee C.-H., Mazdiyasni H., Chopp M. Adenosine kinase inhibition protects brain against transient focal ischemia in rats. Eur. J. Pharmacol. 320:1997;131-137.
131. 2 receptor activation attenuates reperfusion injury by inhibiting neutrophil accumulation, superoxide generation, and coronary endothelial adherence. J. Pharmacol. Exp. Ther. 1:1997;301-309.
132. Jorgensen H.S., Nakayama H., Raaschou H.O., Olsen T.S. Acute stroke and rehabilitation: an analysis of the direct cost and clinical and social determinants. The Copenhagen stroke study. Stroke. 6:1997;1138-1141.
133. Kalaria R.N., Harik S.I. Adenosine receptors of cerebral microvessels and choroid plexus. J. Cereb. Blood Flow Metab. 6:1986;463-470.
134. Kalimo, H., Kaste, M., Haltia, M., 1997. Vascular diseases. In: Graham, D.I., Lantos, P.L. (Eds.), Greenfield's Neuropathology, 6th edn. Arnold, London, pp. 313-396.
135. Kassell N.F., Boarini D.J., Olin J.J., Sprowell J.A. Cerebral systemic circulatory effect of arterial hypotension induced by adenosine. J. Neurosurg. 1:1983;69-76.
136. Kaste M., Fogelholm R., Rissanen A. Economic burden of stroke and the evaluation of new therapies. Public Health. 2:1998;103-112.
137. Katchman A., Hershkovitz N. Adenosine antagonists prevent hypoxia-induced depression of excitatory but not inhibitory synaptic currents. Neurosci. Lett. 159:1993;123-126.
138. Kempski O.S. Neuroprotection. Models and basic principles. Anesthesist. 43(2):1994;S25-S33.
139. 2 receptors in the inhibition of long term potentiation in the CA1 region of rat hippocampus. Brain Res. 1-2:1997;184-190.
140. Kim Y.B., Gidday J.M., Gonzales E.R., Shah A.R., Park T.S. Effect of hypoglycemia on postischemic cortical blood flow, hypercapnic reactivity, and interstitial adenosine concentration. J. Neurosurg. 6:1994;877-884.
141. 3H ]acetylcholine release J. Neurochem. 3:1994;960-966.
142. 2A receptor is not mediated by increases in cyclic cAMP. J. Neurochem. 6:1995;2801-2809.
143. Kittner B., Rossner M., Rother M. Clinical trials in dementia with propentofylline. Ann. N.Y. Acad. Sci. 826:1997;307-316.
144. 2+]o. Neurosci. Lett. 179:1994;132-136.
145. 2+-dependent manner. Neuroscience. 4:1995;947-953.
146. Knutsen, L.J.S., Lau, J., Sheardown, M.J., Eskesen, K., Thomsen, C., Weis, J.U., Judge, M.E., Klitgaard, H., 1995. Anticonvulsant actions of novel and reference adenosine agonists. In: Belardinelli, L., Pelleg, A. (Eds.), Adenosine and Adenine Nucleotides: From Molecular Biology to Integrative Physiology. Kluwer Academic Publishers, Boston, pp. 479-487.
147. Kogure K., Yamasaki Y., Matsuo Y., Kato H., Onodera H. Inflammation of the brain after ischemia. Acta Neurochir. Suppl. 66:1996;40-43.
148. Kokomen E., Whishnat J.P., O'Fallon W.M., Chu C.P., Beard C.M. Dementia after ischemic stroke: a population-based study in Rochester, Minnesota. Neurology. 3:1996;852-853.
149. Koroshetz W., Moskowitz M. Emerging treatments for stroke in humans. Trends Pharmacol. Sci. 6:1996;227-233.
150. Kostopoulos G.K., Phillis J.W. Purinergic depression of neurons in different areas of the brain. Exp. Neurol. 55:1977;719-724.
151. Kulinski V.I., Olkhovski I.A., Kovalevski A.N. Biochemico-pharmacological mechanisms and the relation between anticalorigenic, hypothermic, and antihypoxic effects of adenosine. Vopr. Med. Khim. 3:1987;107-112.
152. Lanier W.L. Cerebral metabolic rate and hypothermia: their relationship with ischemic neurologic injury. J. Neurosurg. Anesthesiol. 3:1995;216-221.
153. 2 adenosine receptors: their presence and neuromodulatory role in the central nervous system. Gen. Pharmacol. 6:1996;925-933.
154. 1 receptors. Brain Res. 260:1983;156-159.
155. 3 receptor: sustained cardioprotection. Proc. Natl. Acad. Sci. USA. 95:1998;6995-6999.
156. 3 reception: pharmacological properties, species differences, and receptor functions. Trends Pharmacol. Sci. 8:1994;298-306.
157. 1 adenosine receptors. FASEB J. 12:1995;2668-2676.
158. 2B adenosine receptors. Life Sci. 17-18:1998;1519-1524.
159. Lipper B., Bell A., Gaynor B. Recurrent hypotension immediately after seizure in nortryptiline overdose. Am. J. Emerg. Med. 4:1994;452-453.
160. Lobner D., Choi D.W. Dipyridamole increase oxygen-glucose deprivation-induced injury in cortical cell culture. Stroke. 10:1994;2085-2089.
161. Longuemere M.C., Swanson R.A. Excitatory amino acid release from astrocytes during energy failure by reversal of sodium-dependent uptake. J. Neurosci. Res. 3:1995;379-386.
162. Lupica C.R., Procotr W.R., Dunwiddie T.V. Presynaptic inhibition of excitatory synaptic transmission by adenosine in rat hippocampus: analysis of unitary EPSP variance measured by whole-cell recording. J. Neurosci. 10:1992;3753-3764.
163. Mager R., Ferroni S., Schubert P. Adenosine modulates a voltage-dependent chloride conductance in cultured hippocampal neurons. Brain Res. 532:1990;58-62.
164. Manzoni O.J., Manabe T., Nicoll R.A. Release of adenosine by activation of NMDA receptors in the hippocampus. Science. 265:1994;2098-2101.
165. Mather J., Hachinski V. Hypothermia as a potential treatment for cerebral ischemia. Cerebrovasc. Brain Metab. Rev. 4:1993;277-300.
166. Matsumoto K., Graf R., Rosner G., Schimada N., Weiss W.D. Flow thresholds for extracellular purine catabolite elevation in rat focal ischemia. Brain Res. 579:1992;309-314.
167. Matsumoto K., Sakaki T., Kohmura E., Hayakawa T., Yamada K. Amelioration of ischemic brain damage by the preischemic administration of propentofylline (HWA 285) in a rat focal ischemia. Brain Res. 1-2:1996;228-230.
168. McCulloch J. Neuroprotective drug development in stroke: blood pressure and its impact. J. Hypertens. Suppl. 5:1996;S131-S136.
169. 3 receptors on macrophages inhibits necrosis factor-alpha. Eur. J. Pharmacol. 23:1996;209-216.
170. Meden P., Kammersgaard L., Overgaard K. Can acute stroke be treated with hypothermia? Nord. Med. 1:1998;3-5.
171. 1 receptors and constitutive P2 purinoceptors in CHO-K1 cells. Br. J. Pharmacol. 8:1995;1415-1424.
172. Miller L.P., Hsu C. Therapeutic potential for adenosine receptor activation in ischemic brain injury. J. Neurotrauma. 9(2):1992;S563-S577.
173. Miller L.P., Jelovich L.A., Yao L., Da Re J., Ugarkar B., Foster C. Pre- and peristroke treatment with the adenosine kinase inhibitor, 5′-deoxyiodotuberacin, significantly reduces infarct volume after temporary occlusion of the middle cerebral artery in rats. Neurosci. Lett. 2:1996;73-76.
174. Mitani A., Andou Y., Matsuda S., Arai T., Sakanaka M., Kataoka K. Origin of ischemia-induced glutamate efflux in the CA1 field of the gerbil hippocampus: an in vivo brain microdialysis study. J. Neurochem. 6:1994;2152-2164.
175. Mitchell J.B., Lupica C.R., Dunwiddie T.V. Activity dependent release of endogenous adenosine modulates synaptic responses in the rat hippocampus. J. Neurosci. 8:1993;3439-3447.
176. Miyashita K., Nkajima T., Ishikawa A., Miyataka T. An adenosine uptake blocker, propentofylline, reduces glutamate release in gerbil hippocampus. Neurochem. Res. 2:1992;147-150.
177. 2A receptors in regulating GABAergic synaptic transmission in striatal medium spiny neurons. J. Neurosci. 2:1996;605-611.
178. Mullane K., Bullough D. Harnessing an endogenous cardioprotective mechanism: cellular sources and sites of action of adenosine. J. Mol. Cell. Cardiol. 4:1995;1041-1054.
179. Mustard J.F., Rowsell H.C., Murphy E.A. Platelet economy (platelet survival and turnover). Br. J. Haematol. 1:1966;1-24.
180. 1 receptor binding in the post-ischaemic rat brain. Neuroreport. 5:1994;1453-1456.
181. Newby A.C. Adenosine as a retaliatory metabolite. Trends Biol. Sci. 9:1984;42-44.
182. 2 receptor. Naunyn-Schmiedeberg's Arch. Pharmacol. 2:1992;234-237.
183. Obrenovich, T.P., Gurcharan, S.S., Symon, L., 1990. Ionic homeostasis and neurotransmitter changes in ischemia. In: Krieglstein, J., Oberpichler, H. (Eds.), Pharmacology of Cerebral Ischemia. WVG, Stuttgart, pp. 97-112.
184. Olney J.W., Wozniak D.F., Farber N.B. Excitotoxic neurodegeneration in Alzheimer disease new hypothesis and new therapeutic strategies. Arch. Neurol. 10:1997;1234-1240.
185. 2A receptors. Trends Pharmacol. Sci. 10:1996;364-372.
186. 2A receptors and neuroprotection. Ann. N.Y. Acad. Sci. 825:1997;30-48.
187. Onodera H., Kogure K. Autoradiographic visualization of adenosine A1 receptors in the gerbil brain hippocampus: changes in the receptor density after transient ischemia. Brain Res. 345:1985;406-408.
188. 1 binding sites after transient forebrain ischemia in the gerbil. Brain Res. 458:1989;212-217.
189. Ontyd J., Schrader J. Measurement of adenosine, inosine, and hypoxanthine in human plasma. J. Chromatogr. 2:1984;404-409.
190. 2 receptor agonist CGS 21680 enhances excitatory transmitter release from ischemic rat cerebral cortex. Neurosci. Lett. 138:1992;169-172.
191. Palmer T.M., Stiles G.L. Neurotransmitter receptors VII: adenosine receptors. Neuropharmacology. 34:1995;683-694.
192. Palmer T.M., Stiles G.L. Structure-function analysis of inhibitory adenosine receptor regulation. Neuropharmacology. 9:1997;1141-1147.
193. Pancioli A.M., Broderick J., Kotari R., Brott T., Tuchfarber A., Miller R., Khoury J., Jauch E. Public perception of stroke warning signs and knowledge of potential risk factors. JAMA. 279:1998;1288-1292.
194. Park T.S., Gidday J.M. Effect of dipyridamole on cerebral extracellular adenosine level in vivo. J. Cereb. Blood Flow Metab. 3:1990;424-427.
195. Park C.K., Rudolphi K.A. Antiischemic effects of propentofylline (HWA 285) against focal cerebral ischemia in rats. Neurosci. Lett. 2:1994;235-238.
196. Park T.S., Gidday J.M., Gonzales E. Local cerebral blood flow response to locally infused 2-chloroadenosine during hypotension in piglets. Brain Res. Dev. Brain Res. 1:1991;73-77.
197. Parkinson F.E., Rudolphi K.A., Fredholm B.B. Propentofylline: a nucleoside transport inhibitor with neuroprotective effects in cerebral ischemia. Gen. Pharmacol. 6:1994;1053-1058.
198. i. J. Biol. Chem. 262:1987;841-847.
199. 2B-receptor mediated cyclic AMP accumulation in primary rat astrocytes. Br. J. Pharmacol. 1:1994;191-198.
200. Pellegrino D.A., Wang Q., Koenig H., Albrecht R.F. Role of nitric oxide, adenosine, N-methyl-D-aspartate receptors, and neuronal activation in hypoxia-induced pial arteriolar dilation in rats. Brain Res. 704:1995;61-70.
201. Pellerin L., Magistretti P.J. Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. Proc. Natl. Acad. Sci. USA. 22:1994;10625-10629.
202. Phillis J.W. Adenosine in the control of cerebral circulation. Cerebrovasc. Brain Metab. Rev. 1:1989;26-54.
203. Phillis, J.W., 1990. Adenosine, inosine, and oxypurines in cerebral ischemia. In: Schurr, A., Rigor, B.M. (Eds.), Cerebral Ischemia and Resuscitation. CRC Press, Boca Raton, FL, pp. 189-204.
204. Phillis, J.W., 1993. Cerebral vascular responses to hypoxia, hyper- and hypocapnia, and hypotension. In: Phillis, J.W. (Ed.), The Regulation of Cerebral Blood Flow. CRC Press, Boca Raton, FL, pp. 249-265.
205. Picano E., Abbracchio M.P. European stroke prevention study-2 results: serendipitous demonstration of neuroprotection by endogenous adenosine accumulation? Trends Pharmacol. Sci. 1:1998;14-16.
206. 2-adrenergic receptors permit receptor resensitization. Mol. Pharmacol. 47:1995;666-676.
207. 2A receptor stimulation enhances striatal glutamate levels. Eur. J. Pharamacol. 2:1995;215-217.
208. 2) receptor selective agonists. Int. J. Immunol. 3:1995;221-224.
209. Prince D.A., Stevens C.F. Adenosine decreases neurotransmitter release at central synapses. Proc. Natl. Acad. Sci. USA. 89:1992;8586-8590.
210. 3R is the unique adenosine receptor which facilitates release of allergic mediators in mast cells. J. Biol. Chem. 268:1993;16887-16890.
211. Reith J., Jorgensen H.S., Pedersen P.M., Nakayama H., Raaschou H.O., Jeppesen L.L., Olesen T.S. Body temperature in acute stroke: relation to stroke severity, infarct size, mortality, and outcome. Lancet. 9012:1996;1415-1416.
212. 1 adenosine receptors in rat brain with emphasis on localization in the hippocampal formation, cerebral cortex, cerebellum, and basal ganglia. Brain Res. 2:1995;193-203.
213. Rother M., Kittner B., Rudolphi K., Rossner M., Labs K.H. HWA 285 (propentofylline) - a new compound for the treatment of both vascular dementia and dementia of the Alzheimer type. Ann. N.Y. Acad. Sci. 777:1996;404-409.
214. Rouleau A., Dimitriadou V., Trung Tuong M.D., Newlands G.F., Miller H.R., Schwartz J.C., Garbarg M. Mast cell specific protease in rat brain: changes in rats with experimentalallergic encephalomyelitis. J. Neural Transm. 4-5:1997;399-417.
215. Rudolphi K.A., Schubert P., Parkinson F.E., Fredholm B.B. Adenosine and brain ischemia. Cerebrovasc. Brain Metab. Rev. 4:1992;346-369.
216. Salomon J.E., Cronstein B.N. Fcgamma receptor-mediated functions in neutrophils are modulated by adenosine receptor occupancy: A1 receptor are stimulatory and A2 receptors are inhibitory. J. Immunol. 145:1990;2235-2240.
217. 2 receptor regulation of striatal gene expression. In: Belardinelli, L., Pelleg, A. (Eds.), Adenosine and Adenine Nucleotides: From Molecular Biology to Integrative Physiology. Kluwer Academic Publishers, Boston, pp. 71-76.
218. Schilling L., Wahl M. Brain edema: pathogenesis and therapy. Kidney Int. Suppl. 59:1997;S69-S75.
219. Scholz K.P., Miller R.J. Inhibition of quantal transmitter release in the absence of calcium influx by a G-protein-linked adenosine receptor a hippocampal synapses. Neuron. 8:1992;1139-1150.
220. Schrader J., Wahl M., Kuschinsky G.W. Increase of adenosine content in cerebral cortex of the cat during bicuculine-induced seizure. Pflügers Arch. 3:1980;245-251.
221. Schubert, P., Kreutzberg, G.W., 1990. Neuroprotective mechanisms of endogenous adenosine action and pharmacological implications. In: Krieglstein, J., Oberpichler, H. (Eds.), Pharmacology of Cerebral Ischemia. WVG, Stuttgart, pp. 417-426.
222. 2+ frequency depends on endogenous adenosine. Int. J. Purine Pyrimidine Res. 2:1991;11-16.
223. Schubert P., Rudolphi K., Fredholm F., Nakamura Y. Modulation of nerve and glial cell function by adenosine - role in development of ischemic brain damage. Int. J. Biochem. 26:1994;1227-1236.
224. Schubert P., Ogata T., Marchini C., Frerroni S., Rudolphi K. Protective mechanisms of adenosine in neurons and glial cells. Ann. N.Y. Acad. Sci. 825:1997;1-10.
225. Schwab S., Horn M., Spranger M., Hacke W. Therapeutic hypothermia after cerebral ischemia. Theoretical principles and possible clinical applications. Nervenarzt. 12:1994;828-835.
226. Sciotti V.M., Roche F.M., Grabb M.C., van Wylen D.G.L. Adenosine receptor blockade augments interstitial fluid levels of excitatory amino acids during cerebral ischemia. J. Cereb. Blood Flow Metab. 12:1992;646-655.
227. 2 receptor-mediated excitatory actions on the nervous system. Prog. Neurobiol. 3:1996;167-189.
228. Segal M. Intracellular analysis of postsynaptic action of adenosine in the rat hippocampus. Eur. J. Pharmacol. 79:1992;193-199.
229. Segal M., Rogawski M.A., Barker J.L. A transient potassium conductance regulates the excitability of cultured hippocampal and spinal neurons. Brain Res. 4:1984;604-609.
230. Sei Y., Von Lubitz D.K.J.E., Abbracchio M.P., Ji X.D., Jacobson K.A. Adenosine A3 receptor agonist-induced neurotoxicity in rat cerebellar granule neurons. Drug. Dev. Res. 40:1997;267-273.
231. 2) antagonist inhibits induction of long-term potentiation of evoked synaptic potentials but not the population spike in hippocampal CA1 neurons. Biochem. Biophys. Res. Commun. 3:1991;1991.
232. Selman W.R., Tarr R., Landis D.M.D. Brain attack: emergency treatment of ischemic stroke. Am. Fam. Phys. 8:1997;2655-2662.
233. Serrander L., Fallman M., Stendahl O. Activation of phospholipase D is an early event in integrin-mediate signaling leading to phagocytosis in human neutrophils. Inflammation. 4:1996;39-50.
234. Sheardown, M., Hansen, A.J., Thomasen, C., Judge, M.E., Knutsen, L.S.J., 1994. Novel adenosine agonists: a strategy for stroke therapy. In: Grotta, J., Miller, L.P., Buchan, A.M., Sussman, C. (Eds.), Ischemic Stroke: Recent Advances in Understanding and Therapy. Southborough, MA, pp. 187-214.
235. Shinoda J., Furukawa Y., Furukawa S. Stimulation of nerve growth factor synthesis/secretion by propentofylline in cultured astroglial cells. Biochem. Pharmacol. 39:1990;1813-1816.
236. Shryok J.C., Belardinelli L. Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology. Am. J. Cardiol. 12A:1997;2-10.
237. Siggins G.R., Schubert P. Adenosine depression of hippocampal neurons in vitro: an intracellular study of dose-dependent actions on synaptic and membrane potentials. Neurosci. Lett. 23:1981;55-60.
238. Simpson R.E., O'Regan M.H., Perkins L.M., Phillis J.W. Excitatory amino acid release from ischemic rat cerebral cortex: effects of adenosine receptor agonists and antagonists. J. Neurochem. 58:1992;1683-1690.
239. Smith J.A. Exercise, training and red blood cell turnover. Sports Med. (New Zealand). 1:1995;9-31.
240. Sokoloff L. Sites and mechanisms of function-related changes in energy metabolism in the nervous system. Dev. Neurosci. 35:1993;194-206.
241. Squire I.B., Lees K.R., Pryse-Phillips W., Kertesz A., Bamford J. The effects of lifarizine in acute cerebral infarction: a pilot study. Cerebrovasc. Dis. 6:1996;156-160.
242. 3 receptors during prolonged simulated ischemia. J. Physiol. 273:1997;H501-H505. (Heart Circ. Physiol. 42).
243. Stange K., Lagerkranser M., Sollevi A. Effect of adenosine-induced hypotension on the cerebral autoregulation in the anesthetized pig. Acta Anesthesiol. Scand. 6:1989;450-457.
244. Stanimovirovic D.B., Bertrand N., Merkel N., Bembry J., Spatz M. Interaction between histamine and adenosine in human cerebromicrovascular endothelial cells. Metab. Brain Dis. 3:1994;275-289.
245. 2 subtype receptor stimulation. J. Cereb. Blood Flow Metab. 25:1995;1001-1025.
246. Suyama K., Saito K., Chen G., Pan B.S., Manji H.K., Potter W.Z. Alterations in cyclic AMP and G protein subunits following transient ischemia in gerbil hippocampus. J. Cereb. Blood Flow Metab. 5:1995;877-885.
247. Suzuki H., Miura S., Liu Y.Y., Tsuchiya M., Ishii H. Substance P induces degranulation of mast cells and leukocyte adhesion to venular endothelium. Peptides. 8:1995;1447-1452.
248. Suzuki M., Nishina M., Endo M., Matsushita K., Tetsuka M., Shima K., Okuyama S. Decrease in cerebral free magnesium concentration following closed head injury and the effects of VA-045 in rats. Gen. Pharmacol. 1:1997;19-21.
249. 2A receptor messenger RNA in the rat central nervous system with special reference to dopamine innervated areas. Neuroscience. 4:1997;1171-1185.
250. 1 receptors are located predominantly on axons in the rat hippocampus. J. Comp. Neurol. 4:1995;517-531.
251. Swanson R.A., Farell K., Simon R.P. Acidosis causes failure of astrocyte glutamate uptake during hypoxia. J. Cereb. Blood Flow Metab. 3:1995;417-424.
252. Swanson T.H., Krahl S.E., Liu Y.Z., Drazba J.A., Rivkees S.A. Evidence for physiologically active adenosine receptors in the rat corpus callosum. Brain Res. 1-2:1998;188-198.
253. Sweeney M.I. Neuroprotective effects of adenosine in cerebral ischemia: window of opportunity. Neurosci. Biobehav. Rev. 2:1997;207-217.
254. Taboulet P., Michard F., Muszynski J., Galliot-Guilley M., Bismuth C. Cardiovascular repercussions of seizures during cyclic antidepressant poisoning. J. Toxicol. Clin. Toxicol. 3:1995;205-211.
255. Tanaka K., Fukuuchi Y., Nozaki H., Nagata E., Kondo T., Dembo T. Acute ischemic vulnerability of PKA in the dendritic subfields of the hippocampus. Neuroreport. 11:1997;2423-2428.
256. Taylor T.N. The medical economics of stroke. Drugs (New Zealand). 54(3):1997;51-57.
257. 2 receptors, adenosine inhibits the production of tumor necrosis factor-alpha of endotoxin-stimulated human polymorphonuclear leukocytes. J. Lab. Clin. Med. 3:1995;275-282.
258. 2 receptors differentially modulates calcium channels and glycinergic transmission in rat brainstem. Neuron. 13:1994;1439-1446.
259. van Calker D., Müller M., Hamprecht G. Adenosine regulates via two different types of receptors the accumulation of cyclic AMP in cultured brain cells. J. Neurochem. 33:1979;999-1005.
260. Vink R., Heath D.L., McIntosh T.K. Acute and prolonged alterations of brain free magnesium following fluid percussion-induced brain trauma in rats. J. Neurochem. 6:1996;2477-2483.
261. Von Lubitz, D.K.J.E., 1997. Acute treatment of cerebral ischemia and stroke: put out more flags. In: Jacobson, K.A., Jarvis, M.E. (Eds.), Purinergic Approaches in Experimental Therapeutics. Wiley-Liss, New York, pp. 449-470.
262. 3 receptor and brain: a culprit, a hero, or merely yet another receptor? Ann. N.Y. Acad. Sci. 825:1997;49-67.
263. Von Lubitz, D.K.J.E., Marangos, P.J., 1990. Self-defense of the brain: adenosinergic strategies in neurodegeneration. In: Marangos, P.J., Lal, H. (Eds.), Emerging Strategies in Neurodegeneration. Birkhauser, Boston, pp. 151-186.
264. 3 receptor stimulation and cerebral ischemia. Eur. J. Pharmacol. 263:1994;59-67.
265. Von Lubitz D.K.J.E., Carter M.F., Beenhakker M., Lin R.C.-S., Jacobson K.A. Adenosine: a phototherapeutic concept in neurodegeneration. Ann. N.Y. Acad. Sci. 765:1995;163-178.
266. 2A receptor agonist and antagonist. Eur. J. Pharmacol. 3:1995;295-302.
267. 3 receptor agonist and cerebral ischemia: neuronal and glial effects. Eur. J. Pharmacol.
268. 2-adrenergic receptors between the plasma membrane and endosomes containing transferrin receptors. J. Biol. Chem. 267:1992;3530-3538.
269. Wahl M., Whalley E.T., Unterberg A., Schilling L., Parsons A.A., Beathman A., Young A.R. Vasomotor and permeability effects of bradykinin in the cerebral microcirculation. Immunopharmacology. 1-3:1996;257-263.
270. Wahlgren N.G., McMahon D.G., DeKeyser J., Indredavik B., Ryman T. Intravenous West European Stroke Trial (INWEST) of nimodipine in the treatment of acute ischemia stroke. Cerebrovasc. Dis. 4:1994;204-210.
271. Wang T., Mentzer R.M. Jr., van Wylen D.G. Interstitial adenosine with dipyridamole: effect of adenosine receptor blockade and adenosine deaminase. Am. J. Physiol. 263:1992;PH552-PH558. (Pt.2).
272. 2+ elevations, activation of phospholipase D, and activation of the NADPH oxidase. Biochem. Biophys. Res. Commun. 3:1998;819-826.
273. Wei, E.P., Kontos, H.A., 1993. Cerebrovascular flow regulation by adenosine. In: Phillis, J.W. (Ed.), The Regulation of Cerebral Blood Flow. CRC Press, Boca Raton, FL, pp. 281-295.
274. White, Hoehn, 1991.
275. White P.J., Rose'Myer R.B., Hope J.W. Functional characterization of adenosine receptors in the nucleus tractus solitarius mediating hypertensive responses in the rat. Br. J. Pharmacol. 2:1996;305-308.
276. Whittingham, T.S., 1990. Aspects of brain energy metabolism and cerebral ischemia. In: Schurr, A., Rigor, B.M. (Eds.), Cerebral Ischemia and Resuscitation. CRC Press, Boca Raton, FL, pp. 101-121.
277. Winn H.R., Welsh J.E., Rubio R., Berne R.M. Changes in brian adenosine during bicuculine-induced seizures in rats. Effects of hypoxia and altered systemic blood pressure. Circ. Res. 4:1980;568-577.
278. Wu L.-G., Saggau P. Adenosine inhibits evoked synaptic transmission primarily by reducing presynaptic calcium influx in area CA1 of hippocampus. Neuron. 12:1994;139-1148.
279. Yamasaki Y., Itoyama Y., Kogure K. Involvement of cytokine production in pathogenesis of transient cerebral ischemic damage. Keio J. Med. 3:1996;225-229.
280. 3 antagonists. Biochem. Biophys. Res. Commun. 2:1997;317-322.
281. 2+ channels by adenosine autoreceptors. Nature. 365:1993;256-258.
282. Yong T., Zheng M.Q., Linthicum D.S. Local histamine release increase leukocyte rolling in the cerebral microcirculation of the mouse. Brain Inj. 10:1997;765-774.
283. Yoon K.-W., Rothman S.M. Adenosine inhibits excitatory but not inhibitory synaptic transmission in the rat hippocampus. J. Neurosci. 5:1991;1375-1380.
284. Young-Su P., Ishikawa J. Analysis of mild barbiturate-moderate hypothermia therapy on the authors' 152 cases. No Shinkei Geka. 6:1997;529-535.
285. 3-subtype adenosine receptor is highly expressed in rat vascular smooth cells: its role in attenuating adenosine-induced increase in cAMP. Microvasc. Res. 3:1997;243-252.
286. Zhong W.Q., Todani T., Watanabe Y., Toki A. The effects of adenosine on the energy metabolism of the reperfused intestine in rats. Jpn. J. Surg. 28:1998;178-183.
287. 3 receptor. Proc. Natl. Acad. Sci. USA. 89:1992;7432-7436.
288. Zhu C.Z., Auer R.N. Graded hypotension and MCA occlusion duration: effect in transient focal ischemia. J. Cereb. Blood Flow Metab. 15:1995;980-988.
289. Zimmerman B.J., Granger D.N. Mechanism of reperfusion injury. Am. J. Med. Sci. 4:1994;284-292.
290. Zülküf Önal M., Fisher M. Acute ischemic stroke therapy. Eur. Neurol. 38:1997;141-154.